CA2986766A1 - Immune tolerant and non-immune tolerant elastin-like recombinant peptides and methods of use - Google Patents

Immune tolerant and non-immune tolerant elastin-like recombinant peptides and methods of use

Info

Publication number
CA2986766A1
CA2986766A1 CA2986766A CA2986766A CA2986766A1 CA 2986766 A1 CA2986766 A1 CA 2986766A1 CA 2986766 A CA2986766 A CA 2986766A CA 2986766 A CA2986766 A CA 2986766A CA 2986766 A1 CA2986766 A1 CA 2986766A1
Authority
CA
Canada
Prior art keywords
gly
val
seq
pro
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2986766A
Other languages
English (en)
French (fr)
Inventor
Mingnan CHEN
Hyung Jin Cho
Peng Wang
Shuyun DONG
Peng Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of CA2986766A1 publication Critical patent/CA2986766A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2986766A 2015-05-29 2016-05-27 Immune tolerant and non-immune tolerant elastin-like recombinant peptides and methods of use Pending CA2986766A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562230160P 2015-05-29 2015-05-29
US62/230,160 2015-05-29
US201662309113P 2016-03-16 2016-03-16
US62/309,113 2016-03-16
PCT/US2016/034530 WO2016196249A1 (en) 2015-05-29 2016-05-27 Immune tolerant and non-immune tolerant elastin-like recombinant peptides and methods of use

Publications (1)

Publication Number Publication Date
CA2986766A1 true CA2986766A1 (en) 2016-12-08

Family

ID=57441707

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2986766A Pending CA2986766A1 (en) 2015-05-29 2016-05-27 Immune tolerant and non-immune tolerant elastin-like recombinant peptides and methods of use

Country Status (6)

Country Link
US (1) US11957762B2 (https=)
EP (1) EP3302531B1 (https=)
JP (1) JP6924151B2 (https=)
CN (1) CN107750163A (https=)
CA (1) CA2986766A1 (https=)
WO (1) WO2016196249A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11198722B2 (en) 2017-10-06 2021-12-14 University Of Utah Research Foundation Immune tolerant elastin-like peptide tetramer guided nanoparticles and methods of use

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020048996A1 (en) 2018-09-06 2020-03-12 ETH Zürich Self-assembling globular proteins and uses thereof
CN111346235A (zh) * 2018-12-20 2020-06-30 海南医学院第一附属医院 一种基于弹性靶向多肽的载药纳米颗粒及其制备方法和应用
CA3149274A1 (en) * 2019-08-23 2021-03-04 Mingnan CHEN Immune tolerant elastin-like recombinant peptides and methods of use
EP4035682A1 (en) * 2021-01-29 2022-08-03 Universite De Bordeaux Bioconjugate comprising a photosensitizer unit, method for its preparation and use thereof
KR102718109B1 (ko) * 2021-10-01 2024-10-17 (주)케어젠 탈모 방지 또는 발모 촉진 활성을 갖는 펩타이드와 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5206353A (en) 1988-07-23 1993-04-27 The United States Of America As Represented By The Department Of Health And Human Services CD-4/cytotoxic gene fusions
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5981177A (en) 1995-01-25 1999-11-09 Demirjian; David C. Protein fusion method and constructs
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
AU5065198A (en) * 1996-11-15 1998-06-10 Maria Grazia Masucci Fusion proteins having increased half-lives
EP0973933A1 (en) 1997-02-13 2000-01-26 American National Red Cross Immunological tolerance to hiv epitopes
US7494788B2 (en) * 2005-07-11 2009-02-24 Molecular Kinetics, Inc. Entropic bristle domain sequences and their use in recombinant protein production
US8470967B2 (en) 2010-09-24 2013-06-25 Duke University Phase transition biopolymers and methods of use
US9114128B2 (en) * 2011-09-30 2015-08-25 Protein Genomics, Inc. Tropoelastins and uses thereof
EP3785725A1 (en) * 2013-10-01 2021-03-03 University of Mississippi Medical Center Composition and method for therapeutic agent delivery during pregnancy

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11198722B2 (en) 2017-10-06 2021-12-14 University Of Utah Research Foundation Immune tolerant elastin-like peptide tetramer guided nanoparticles and methods of use
US12162923B2 (en) 2017-10-06 2024-12-10 Univeristy Of Utah Research Foundation Immune tolerant elastin-like peptide tetramer guided nanoparticles and methods of use

Also Published As

Publication number Publication date
US11957762B2 (en) 2024-04-16
EP3302531B1 (en) 2021-02-17
JP2018521977A (ja) 2018-08-09
CN107750163A (zh) 2018-03-02
EP3302531A1 (en) 2018-04-11
US20180289830A1 (en) 2018-10-11
WO2016196249A1 (en) 2016-12-08
EP3302531A4 (en) 2019-02-20
JP6924151B2 (ja) 2021-08-25

Similar Documents

Publication Publication Date Title
EP3302531B1 (en) Immune tolerant and non-immune tolerant elastin-like recombinant peptides and methods of use
Dacoba et al. Polysaccharide nanoparticles can efficiently modulate the immune response against an HIV peptide antigen
Skwarczynski et al. Peptide-based synthetic vaccines
EP2928502B1 (en) Conjugates of proteins and multivalent cell-penetrating peptides and their uses
Moyle et al. Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines
Cho et al. Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriers
WO2016146261A1 (en) Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
CA3010779A1 (en) Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
CN104404068A (zh) 免疫应答的引发
Choi et al. Protein cage nanoparticles as delivery nanoplatforms
AU2021402007A9 (en) Covalently modified antigens for improved immune response and/or stability
Simerska et al. Modern lipid‐, carbohydrate‐, and peptide‐based delivery systems for peptide, vaccine, and gene products
Rudra et al. Supramolecular peptide nanofibers engage mechanisms of autophagy in antigen-presenting cells
US20230090311A1 (en) Self-assembling, self-adjuvanting system for delivery of vaccines
Zhang et al. Advances in cytosolic delivery of proteins: approaches, challenges, and emerging technologies
Kwon et al. Engineering encapsulin nanocages for drug delivery
Baruah et al. The emergence of nanovaccines as a new paradigm in virological vaccinology: a review
Dong et al. A comparison study of iTEP nanoparticle-based CTL vaccine carriers revealed a surprise relationship between the stability and efficiency of the carriers
KR101579879B1 (ko) ｓｉＲＮＡ 전달을 위한 히알루론산-콜레스테롤 나노파티클 및 이를 포함하는 조성물
KR20220144830A (ko) 펩티드-멜라닌 결합 최적화
Miliotou et al. In Vitro-Transcribed mRNAs as a New Generation of Therapeutics in the Dawn of Twenty-First Century: Exploitation of Peptides as Carriers for Their Intracellular Delivery
Henry Self-Assembled Nucleic Acid Nanomaterials for Biomedical Applications or Structural Determination of Guest Molecules
Pho Surface Engineering of Protein Nanoparticles for Intranasal Delivery
Tofik et al. Rational design and preclinical evaluation of elastin-like polypeptide micelle nanoparticles for drug delivery
Ramirez Engineering Protein-Based Nanoparticles for Infectious Disease Vaccine Development

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210514

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250304

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250523

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250523

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250704